Global Artificial Intelligence (AI) in Healthcare Collaboration and Licensing Deals Analysis Report 2023 with a Directory of 869 Deals – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Artificial Intelligence (AI) Collaboration and Licensing Deals 2016-2023” report has been added to ResearchAndMarkets.com’s offering.

This report contains a comprehensive listing of 863 artificial intelligence deals announced since 2016 including financial terms where available, including links to online deal records of actual artificial intelligence partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Artificial Intelligence (AI) Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the artificial intelligence deals entered into by the worlds leading biopharma companies. Fully revised and updated, the report provides details of artificial intelligence deals from 2016 to 2023.

The report provides a detailed understanding and analysis of how and why companies enter artificial intelligence deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. The report includes collaboration, development, research and licensing deals.

The report also includes numerous table and figures that illustrate the trends and activities in artificial intelligence deal making since 2016.

In addition, a comprehensive deal directory is provided organized by company A-Z, deal type and therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Artificial Intelligence (AI) Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse artificial intelligence collaboration and licensing deals
• Benchmark analysis – identify market value of transactions
• Financials terms – upfront, milestone, royalties
• Directory of deals by company A-Z, deal type and therapy area
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents – insights into deal structures
• Due diligence – assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Trends in artificial intelligence dealmaking

2.1. Introduction

2.2. Artificial intelligence deals over the years

2.3. Most active artificial intelligence dealmakers

2.4. Artificial intelligence deals by deal type

2.5. Artificial intelligence deals by therapy area

2.6. Artificial intelligence deals by industry sector

2.7. Deal terms for artificial intelligence deals

2.7.1 Artificial intelligence deals headline values

2.7.2 Artificial intelligence deal upfront payments

2.7.3 Artificial intelligence deal milestone payments

2.7.4 Artificial intelligence royalty rates

Chapter 3 – Leading artificial intelligence deals

3.1. Introduction

3.2. Top artificial intelligence deals by value

Chapter 4 – Most active artificial intelligence dealmakers

4.1. Introduction

4.2. Most active artificial intelligence dealmakers

4.3. Most active artificial intelligence deals company profiles

Chapter 5 – Artificial intelligence contracts dealmaking directory

5.1. Introduction

5.2. Artificial intelligence contracts dealmaking directory

Chapter 6 – Artificial intelligence dealmaking by technology type

Deal directory

Deal directory – Artificial intelligence deals by company A-Z

Deal directory – Artificial intelligence deals by deal type

Deal directory – Artificial intelligence deals by therapy area

Companies Mentioned Partial)

• HistoIndex
• Medicines and Healthcare Products Regulatory Agency
• Boehringer Ingelheim
• Worthington Biochemical Corporation
• Loop Insights
• Roux Institute
• Wyss Institute
• Endpoint Health
• EndPoint Technologies
• MILA International
• Lore IO
• CoreBiome
• Relation Therapeutics
• DecisionQ
• KBP BioSciences
• AUM Biosciences
• SOM Biotech
• Vir Biotechnology
• 1ST Biotherapeutics
• BurstIQ
• Covaris
• Genesis Therapeutics
• C4X Discovery
• Atomwise
• IrisVision
• PolarisQB
• ChemDiv
• Adaptive Biotechnologies
• Kebotix
• AltaML
• Medial
• Reveal Biosciences
• Medial EarlySign
• Global Good Fund
• Mendel Health

For more information about this report visit https://www.researchandmarkets.com/r/praqef

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900